ArticleAmerican journal of translational research2025
Assessment of mammographic and ultrasonic signatures for differentiating benign and malignant breast structural distortions.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the diagnostic performance of mammography and ultrasonography in distinguishing benign from malignant breast structural distortions and to develop an integrated predictive model combining radiomic features and molecular markers for improved risk stratification.
methodsThis retrospective study included 260 patients with histopathologically confirmed breast structural distortions (156 malignant, 104 benign). Lesions were characterized using Breast Imaging Reporting and Data System (BI-RADS) criteria. Radiomic features were extracted with PyRadiomics, harmonized via ComBat, and selected using Least Absolute Shrinkage and Selection Operator (LASSO) regression. A predictive model incorporated imaging features, molecular markers (vascular endothelial growth factor [VEGF], transforming growth factor-β1 [TGF-β1]), and clinical variables. Diagnostic accuracy was assessed by sensitivity, specificity, AUC, and decision curve analysis, with subgroup analyses by age, menopausal status, and breast density.
resultsMalignant distortions showed higher rates of spiculated margins (82.1% vs. 16.3%, P<0.001) and hypoechoic irregular masses (78.2% vs. 27.9%, P<0.001). Combined mammography-ultrasound assessment improved diagnostic performance (AUC 0.91) versus single modalities (mammography 0.79; ultrasound 0.82). The radiomic-molecular model further enhanced accuracy (AUC 0.94) and reduced unnecessary biopsies by 32%. Spiculation complexity and VEGF overexpression were independent predictors of lymphovascular invasion and lower 5-year disease-free survival (68% vs. 89%, P=0.01).
conclusionIntegrating mammography, ultrasonography, and radiomic-pathologic markers significantly improves differentiation of malignant breast distortions and supports personalized prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.